PYPD News and Press, PolyPid Ltd. From 11/24/20

The FDA grants Breakthrough Therapy Designation to PolyPid's (PYPD) lead product candidate D-PLEX100 for the prevention of post-abdominal surgery incisional infection (soft tissue).Breakthrough Therapy status provides for more intensive guidance from the FDA on development...

PETAH TIKVA, Israel, Nov. 24, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that D-PLEX ...

PolyPid Ltd. (PYPD) Q3 2020 Earnings Conference Call November 11, 2020 8:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Amir Weisberg - Chief Executive Officer Dikla Akselbrad - Executive Vice President and Chief Financial Officer Conference Call Participants Gary Nachman - BMO Ca...

PolyPid (PYPD): Q3 GAAP EPS of -$0.35.Cash, cash equivalents and short term deposits of $43.7MPress Release For further details see: PolyPid reports Q3 results

•  Over 50% of p lanned 60 centers for ongoing Phase 3 SHIELD I t rial of D-PLEX 100 in a bdominal s urgery have r eceived IRB approval •  Phase 3 SHIELD II t rial a ...

PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announce...

PETAH TIKVA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announce...

PolyPid Ltd. (PYPD) Q2 2020 Results Conference Call August 19, 2020 08:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Amir Weisberg - Chief Executive Officer Dikla Czaczkes - Executive Vice President and Chief Financial Officer Taunia Markvicka - Chief Operating Off...

PolyPid (NASDAQ: PYPD ) : Q2 Non-GAAP net loss of $4.8M; GAAP net loss of $19.1M. More news on: PolyPid Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

Initiated Phase 3 SHIELD I Trial for D-PLEX 100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX 100 from FDA Presented Positive Phase 2 Results of D-PLEX 100 for Prevention of Surgical Site Infections in Abdominal Surgery at ASCRS Meeting Completed Initial...